Literature DB >> 24764300

A novel intracellular peptide derived from g1/s cyclin d2 induces cell death.

Christiane B de Araujo1, Lilian C Russo2, Leandro M Castro1, Fábio L Forti2, Elisabete R do Monte1, Vanessa Rioli3, Fabio C Gozzo4, Alison Colquhoun5, Emer S Ferro6.   

Abstract

Intracellular peptides are constantly produced by the ubiquitin-proteasome system, and many are probably functional. Here, the peptide WELVVLGKL (pep5) from G1/S-specific cyclin D2 showed a 2-fold increase during the S phase of HeLa cell cycle. pep5 (25-100 μm) induced cell death in several tumor cells only when it was fused to a cell-penetrating peptide (pep5-cpp), suggesting its intracellular function. In vivo, pep5-cpp reduced the volume of the rat C6 glioblastoma by almost 50%. The tryptophan at the N terminus of pep5 is essential for its cell death activity, and N terminus acetylation reduced the potency of pep5-cpp. WELVVL is the minimal active sequence of pep5, whereas Leu-Ala substitutions totally abolished pep5 cell death activity. Findings from the initial characterization of the cell death/signaling mechanism of pep5 include caspase 3/7 and 9 activation, inhibition of Akt2 phosphorylation, activation of p38α and -γ, and inhibition of proteasome activity. Further pharmacological analyses suggest that pep5 can trigger cell death by distinctive pathways, which can be blocked by IM-54 or a combination of necrostatin-1 and q-VD-OPh. These data further support the biological and pharmacological potential of intracellular peptides.
© 2014 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Anticancer Drug; Apoptosis; Cell Cycle; Cell Death; Necrosis (Necrotic Death); Peptides; Proteasome

Mesh:

Substances:

Year:  2014        PMID: 24764300      PMCID: PMC4059116          DOI: 10.1074/jbc.M113.537118

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  83 in total

1.  Peptide diffusion, protection, and degradation in nuclear and cytoplasmic compartments before antigen presentation by MHC class I.

Authors:  Eric Reits; Alexander Griekspoor; Joost Neijssen; Tom Groothuis; Kees Jalink; Peter van Veelen; Hans Janssen; Jero Calafat; Jan Wouter Drijfhout; Jacques Neefjes
Journal:  Immunity       Date:  2003-01       Impact factor: 31.745

2.  Q-VD-OPh, a broad spectrum caspase inhibitor with potent antiapoptotic properties.

Authors:  T M Caserta; A N Smith; A D Gultice; M A Reedy; T L Brown
Journal:  Apoptosis       Date:  2003-08       Impact factor: 4.677

3.  Survival of the fitters.

Authors:  Hans-Georg Rammensee
Journal:  Nature       Date:  2002-10-03       Impact factor: 49.962

4.  Designing isoform-specific peptide disruptors of protein kinase A localization.

Authors:  Lora L Burns-Hamuro; Yuliang Ma; Stefan Kammerer; Ulrich Reineke; Chris Self; Charles Cook; Gary L Olson; Charles R Cantor; Andreas Braun; Susan S Taylor
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-19       Impact factor: 11.205

5.  Controlling deuterium isotope effects in comparative proteomics.

Authors:  Roujian Zhang; Cathy S Sioma; Robert A Thompson; Li Xiong; Fred E Regnier
Journal:  Anal Chem       Date:  2002-08-01       Impact factor: 6.986

6.  A major role for TPPII in trimming proteasomal degradation products for MHC class I antigen presentation.

Authors:  Eric Reits; Joost Neijssen; Carla Herberts; Willemien Benckhuijsen; Lennert Janssen; Jan Wouter Drijfhout; Jacques Neefjes
Journal:  Immunity       Date:  2004-04       Impact factor: 31.745

7.  Necrotic cell death in response to oxidant stress involves the activation of the apoptogenic caspase-8/bid pathway.

Authors:  Xue Wang; Stefan W Ryter; Chunsun Dai; Zi-Lue Tang; Simon C Watkins; Xiao-Ming Yin; Ruiping Song; Augustine M K Choi
Journal:  J Biol Chem       Date:  2003-05-15       Impact factor: 5.157

8.  Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells.

Authors:  M Jane Arboleda; John F Lyons; Fairooz F Kabbinavar; Mark R Bray; Bryan E Snow; Raul Ayala; Mordechai Danino; Beth Y Karlan; Dennis J Slamon
Journal:  Cancer Res       Date:  2003-01-01       Impact factor: 12.701

Review 9.  The CD95(APO-1/Fas) DISC and beyond.

Authors:  M E Peter; P H Krammer
Journal:  Cell Death Differ       Date:  2003-01       Impact factor: 15.828

10.  Novel natural peptide substrates for endopeptidase 24.15, neurolysin, and angiotensin-converting enzyme.

Authors:  Vanessa Rioli; Fabio C Gozzo; Andrea S Heimann; Alessandra Linardi; José E Krieger; Cláudio S Shida; Paulo C Almeida; Stephen Hyslop; Marcos N Eberlin; Emer S Ferro
Journal:  J Biol Chem       Date:  2002-12-24       Impact factor: 5.157

View more
  15 in total

1.  Discovery of Missing Methylation Sites on Endogenous Peptides of Human Cell Lines.

Authors:  Xin Yan; Lingjun Li; Chenxi Jia
Journal:  J Am Soc Mass Spectrom       Date:  2019-08-19       Impact factor: 3.109

2.  Pep5, a Fragment of Cyclin D2, Shows Antiparasitic Effects in Different Stages of the Trypanosoma cruzi Life Cycle and Blocks Parasite Infectivity.

Authors:  Christiane Bezerra de Araujo; Loyze Paola de Lima; Simone Guedes Calderano; Flávia Silva Damasceno; Ariel M Silber; Maria Carolina Elias
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

3.  Reduced Levels of Proteasome Products in a Mouse Striatal Cell Model of Huntington's Disease.

Authors:  Sayani Dasgupta; Michael A Fishman; Hana Mahallati; Leandro M Castro; Alexandre K Tashima; Emer S Ferro; Lloyd D Fricker
Journal:  PLoS One       Date:  2015-12-21       Impact factor: 3.240

Review 4.  Intracellular Peptides in Cell Biology and Pharmacology.

Authors:  Christiane B de Araujo; Andrea S Heimann; Ricardo A Remer; Lilian C Russo; Alison Colquhoun; Fábio L Forti; Emer S Ferro
Journal:  Biomolecules       Date:  2019-04-16

Review 5.  Peptides from Natural or Rationally Designed Sources Can Be Used in Overweight, Obesity, and Type 2 Diabetes Therapies.

Authors:  Mayara C F Gewehr; Renata Silverio; José Cesar Rosa-Neto; Fabio S Lira; Patrícia Reckziegel; Emer S Ferro
Journal:  Molecules       Date:  2020-02-29       Impact factor: 4.411

6.  Effects of the properties of short peptides conjugated with cell-penetrating peptides on their internalization into cells.

Authors:  Ryo Matsumoto; Mina Okochi; Kazunori Shimizu; Kei Kanie; Ryuji Kato; Hiroyuki Honda
Journal:  Sci Rep       Date:  2015-08-10       Impact factor: 4.379

7.  Proteasome inhibitors alter levels of intracellular peptides in HEK293T and SH-SY5Y cells.

Authors:  Sayani Dasgupta; Leandro M Castro; Russell Dulman; Ciyu Yang; Marion Schmidt; Emer S Ferro; Lloyd D Fricker
Journal:  PLoS One       Date:  2014-07-31       Impact factor: 3.240

8.  Cell cycle checkpoint control: The cyclin G1/Mdm2/p53 axis emerges as a strategic target for broad-spectrum cancer gene therapy - A review of molecular mechanisms for oncologists.

Authors:  Erlinda M Gordon; Joshua R Ravicz; Seiya Liu; Sant P Chawla; Frederick L Hall
Journal:  Mol Clin Oncol       Date:  2018-06-14

Review 9.  Cell Penetrating Peptides as Molecular Carriers for Anti-Cancer Agents.

Authors:  Antonella Borrelli; Anna Lucia Tornesello; Maria Lina Tornesello; Franco M Buonaguro
Journal:  Molecules       Date:  2018-01-31       Impact factor: 4.411

10.  Xihuang Pill Induces Apoptosis of Human Glioblastoma U-87 MG Cells via Targeting ROS-Mediated Akt/mTOR/FOXO1 Pathway.

Authors:  Meng Shao; Zhenqiang He; Zhixin Yin; Peihong Ma; Qian Xiao; Yafeng Song; Ziming Huang; Yujie Ma; Yuqin Qiu; Aizhi Zhao; Taicheng Zhou; Qirui Wang
Journal:  Evid Based Complement Alternat Med       Date:  2018-06-26       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.